Oculis Holding (OCS)

• Market cap: $1.2B
• 1 day: -0.72%
• 5 days: -5%
• 1 month: 9.68%
• 3 months: 19.14%
• 6 months: 5.34%
• Year to date: 22.45%
• 1 year: 24.95%
• 5 years: 90.36%
• 10 years: 90.36%
• Sector: Healthcare
• Industry: Biotechnology

About: Oculis Holding AG is a biopharmaceutical company purposefully driven to save sight and improve eye care. It includes OCS-01, a topical retinal candidate for diabetic macular edema (DME); OCS-02, a topical biologic candidate for dry eye disease (DED); and OCS-05, a disease modifying candidate for acute optic neuritis (AON) and other neuro-ophtha disorders such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis.

Employees: 49